All AbMole products are for research use only, cannot be used for human consumption.

Norethindrone is a synthetic progestin, which mimic the actions of the endogenous ovarian hormone progesterone.
| Cell Experiment | |
|---|---|
| Cell lines | Human epithelial cervical cancer cells |
| Preparation method | Thereafter, the cells were incubated with serum-free, phenol-free DMEM for 2 hrs, before treatment with 100 nM DEX, MPA, P4 and NET-A for 1 hr. Cells were crosslinked for 10 min at 37°C with1% formaldehyde and the reaction was stopped with 0.1 mM glycine for 5 min, shaking at room temperature. |
| Concentrations | 100 nM |
| Incubation time | 1 h |
| Animal Experiment | |
|---|---|
| Animal models | Female Sprague-Dawley rats |
| Formulation | corn oil |
| Dosages | 3 μg/rat/day |
| Administration | oral |
| Molecular Weight | 298.42 |
| Formula | C20H26O2 |
| CAS Number | 68-22-4 |
| Form | Solid |
| Solubility (25°C) | DMSO 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Progesterone Receptor Products |
|---|
| Dienogest
Dienogest is an orally-active semisynthetic, steroidal progestogen (or progestin). |
| Gestodene
Gestodene is a synthetic progestin used as a contraceptive. |
| Altrenogest
Altrenogest is a progestogen structurally related to veterinary steroid trenbolone. |
| Dydrogesterone
Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus. |
| Ethynodiol diacetate
Ethynodiol diacetate is one of the first synthetic progestogens used in contraceptive pills. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
